Quest Diagnostics: Growth in Advanced Testing Keeps Me Bullish Despite Medicare Noise
Quest Diagnostics (DGX) is trading near multi-month highs on robust growth in physician, hospital and consumer channels and a fast-growing advanced diagnostics portfolio. Reimbursement uncertainty from Medicare creates headline risk, but a $25.9B market cap, solid cash flow profile, and double-digit growth in higher-margin tests make a mid-term lon…